Tasly Pharmaceutical Group Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tasly Pharmaceutical Group Company Limited with three other
companies in this sector in China:
Shanghai Fosun Pharmaceutical (Group) Company Limited
sales of 14.51 billion Chinese Renmimbi [US$2.13 billion]
of which 70%
was Pharmaceutical Manufacturing and R&D),
Shenzhen Neptunus Bioengineer
(13.61 billion Chinese Renmimbi [US$1.99 billion]
of which 84%
was Pharmaceutical Distribution), and
Harbin Pharmaceutical Group Company Limited
(14.13 billion Chinese Renmimbi [US$2.07 billion]
of which 64%
was Medicine Trade).
Tasly Pharmaceutical Group Company Limited reported sales of 13.95 billion Chinese Renmimbi (US$2.04 billion)
December of 2016.
increase of 5.5%
versus 2015, when the company's sales were 13.22 billion Chinese Renmimbi.
Sales at Tasly Pharmaceutical Group Company Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 112%).
Sales of Medicine Commerce saw an increase
5.3% in 2016, from
6.78 billion Chinese Renmimbi to 7.14 billion Chinese Renmimbi.
Not all segments of Tasly Pharmaceutical Group Company Limited experienced an increase in sales in 2016:
sales of Pharmaceutical and Medicine Manufacturing fell 73.6% to 1.68 billion Chinese Renmimbi.